COMUNICADO DE LILLY ICOS LLC (2)

(Continuación)

About Lilly ICOS LLC

Lilly ICOS LLC, a joint venture between ICOS Corporation (Nasdaq: ICOS) and Eli Lilly and Company (NYSE: LLY), developed tadalafil for the treatment of erectile dysfunction.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs.

ICOS Corporation, a biotechnology company headquartered in Bothell, Washington, is dedicated to bringing innovative therapeutics to patients. ICOS is marketing its first product, Cialis (tadalafil), through Lilly ICOS LLC. ICOS is working to develop treatments for serious unmet medical conditions such as chronic obstructive pulmonary disease, benign prostatic hyperplasia, cancer and inflammatory diseases.

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by the management of ICOS and Lilly. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological, legal and other factors discussed in the two companies' respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies and Lilly ICOS. Results and the timing and outcome of events may differ materially from those expressed or implied by the forward-looking statements in this press release. More specifically, there can be no assurance that Cialis will achieve commercial success or that competing products will not pre-empt market opportunities that might exist for the product.

(1) Cialis(R) is a registered trademark of Lilly ICOS LLC. All other trademarks are the property of their respective owners.

(2) Sexual Encounter Profile - SEP is a self-administered patient diary completed by clinical trial participants after each sexual encounter.

(3) PAIRS is an internationally validated patient questionnaire used to measure behavioural, psychological and relationship outcomes associated with ED and its treatment.

(4) Data were extrapolated from Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ. Impotence and its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study, Journal of Urology. Vol. 151, 54-61, January 1994 and World Population Projection Program Of United Nations (2002 Revision) with indirect standardization.

(5) Shabsigh, R. (2002). Back To Great Sex: Overcome ED and Reclaim Lost Intimacy. New York: Kensington.

(6) Diseases and Conditions: Impotence, http://www.impotence.org/FAQ/index.asp . Data accessed 11.20.03. (7) Lue, Tom F. Erectile Dysfunction. N Engl J Med 2000; 342: 1802-1813.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYICOSLOGO )

Source: Lilly ICOS LLC

Contact: Jane Calloway of Lilly, +1-317-651-5870; or Lacy Fitzpatrick of ICOS, +1-425-415-2207/Photo: http://www.newscom.com/cgi bin/prnh/20040122/LILLYICOSLOGO, PRN Photo Desk, photodesk@prnewswire.com

(1017034)